as Alnylam Picks Inex s Platform Over Protiva s Despite Co-Authoring Study Supporting It in RNAi | GenomeWeb

Alnylam Pharmaceuticals said this week that it has obtained an option to exclusively license a liposomal-based drug-delivery technology from Inex Pharmaceuticals, even though that technology is at the center of a legal thicket that raises doubts about who actually owns the rights to license it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.